» Articles » PMID: 27775094

Pharmacokinetic Comparison Between Quercetin and Quercetin 3-O-β-glucuronide in Rats by UHPLC-MS/MS

Overview
Journal Sci Rep
Specialty Science
Date 2016 Oct 25
PMID 27775094
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Quercetin is a natural flavonoid widely distributed in human diet and functional foods. Quercetin 3-O-β-glucuronide (Q3G) is present in wine and some medicinal plants. Quercetin and Q3G may be metabolized from each other in vivo. While quercetin has been the subject of many studies, the pharmacokinetic profiles of quercetin and Q3G (in animals) have not yet been compared. Herein, we prepared a column-based method for rapid isolation of Q3G from Nelumbo nucifera. Then, we developed an UHPLC-MS/MS method to compare the pharmacokinetics of quercetin and Q3G. Our results showed that the plasma concentration-time curves of quercetin and Q3G show two maxima (T ≈ 0.75 h, T ≈ 5 h). After oral administration of 100 mg/kg quercetin or 100 mg/kg Q3G in rats, predominantly Q3G was detected in plasma with AUC at 39529.2 ± 6108.2 mg·h·L or 24625.1 ± 1563.8 mg·h·L, 18-fold higher than quercetin with AUC at 1583.9 ± 583.3 mg·h·L or 1394.6 ± 868.1 mg·h·L, respectively. After intravenous injection of 10 mg/kg in rats, Q3G showed extensive tissue uptake in kidney (409.2 ± 118.4 ng/g), liver (166.1 ± 52.9 ng/g), heart (97.7 ± 22.6 ng/g), and brain (5.8 ± 1.2 ng/g). In conclusion, we have shown that Q3G is a major active component in plasma and tissue for oral administration of quercetin or Q3G.

Citing Articles

Research advances in : Nutrients, bioactive compounds, and functional properties benefitting livestock.

Zhang S, Yang M, Xu T, Yan Q, Degen A, Zhou X Anim Nutr. 2025; 20:239-248.

PMID: 39990195 PMC: 11847532. DOI: 10.1016/j.aninu.2024.11.005.


Double-Layer Microneedle Patch Loaded with HA-PBA-QCT for Management of Paclitaxel-Induced Peripheral Neuropathic Pain.

Kong Y, Pan T, Liu B, Kuss M, Krishnan M, Alimi O Small. 2025; 21(8):e2409748.

PMID: 39888259 PMC: 11855232. DOI: 10.1002/smll.202409748.


Studying targeted oxidation in diabetic cognitive dysfunction based on scientometrics analysis: research progress of natural product approaches.

Tu W, Xu F, Li J, Tian X, Cao L, Wang L Front Endocrinol (Lausanne). 2025; 15():1445750.

PMID: 39758348 PMC: 11695123. DOI: 10.3389/fendo.2024.1445750.


Pharmacodynamics (PD), Pharmacokinetics (PK) and PK-PD Modeling of NRF2 Activating Dietary Phytochemicals in Cancer Prevention and in Health.

Shannar A, Chou P, Peter R, Dave P, Patel K, Pan Y Curr Pharmacol Rep. 2024; 11(1):6.

PMID: 39649473 PMC: 11618211. DOI: 10.1007/s40495-024-00388-6.


A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.

Frent O, Stefan L, Morgovan C, Duteanu N, Dejeu I, Marian E Int J Mol Sci. 2024; 25(22).

PMID: 39596162 PMC: 11594109. DOI: 10.3390/ijms252212091.


References
1.
Guo X, Zhang D, Gao X, Parry J, Liu K, Liu B . Quercetin and quercetin-3-O-glucuronide are equally effective in ameliorating endothelial insulin resistance through inhibition of reactive oxygen species-associated inflammation. Mol Nutr Food Res. 2013; 57(6):1037-45. DOI: 10.1002/mnfr.201200569. View

2.
Mullen W, Edwards C, Crozier A . Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br J Nutr. 2006; 96(1):107-16. DOI: 10.1079/bjn20061809. View

3.
Hollman P, van Trijp J, Buysman M, van der Gaag M, Mengelers M, de Vries J . Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 1997; 418(1-2):152-6. DOI: 10.1016/s0014-5793(97)01367-7. View

4.
Xing J, Chen X, Zhong D . Absorption and enterohepatic circulation of baicalin in rats. Life Sci. 2005; 78(2):140-6. DOI: 10.1016/j.lfs.2005.04.072. View

5.
Kwon S, Kang M, Huh J, Ha K, Lee J, Lee S . Comparison of oral bioavailability of genistein and genistin in rats. Int J Pharm. 2007; 337(1-2):148-54. DOI: 10.1016/j.ijpharm.2006.12.046. View